For over 25 years, our innovations have significantly improved outcomes for people living with pulmonary arterial hypertension (PAH). Building on this long-standing effort to transform PAH into a manageable condition, we remain committed to discovering new approaches to help patients live better lives every day. Expanding on this core capability, we are pursuing innovative solutions to other complex pulmonary disorders.
A key to this commitment is speed: Revolutionizing the treatment paradigm, reaching patients earlier, removing hurdles to accessing best-in-class oral therapies, and seeking scientifically-mature innovations that can further advance the standard of care and enrich our robust portfolio.
